"Do not dismiss persistent symptoms, no matter how minor they seem. My journey with a rare ovarian cancer taught me that trusting your instincts and seeking immediate medical attention can be the difference between a minor concern and a life-altering diagnosis."
Lisa Carroll’s powerful message resonates deeply, underscoring a critical public health challenge: the often-vague presentation of ovarian cancer symptoms, which can lead to delayed diagnosis, particularly for rare forms. Her personal battle against mucinous ovarian cancer serves as a stark reminder for women to listen to their bodies and advocate for their health, transforming a private struggle into a vital call to action for broader awareness and early intervention.
The insidious nature of ovarian cancer, often dubbed the "silent killer," makes early detection exceptionally challenging. For Lisa Carroll, a 47-year-old mother of three from Coventry, what initially felt like a common ailment quickly escalated into a life-threatening diagnosis of mucinous ovarian cancer (MOC), one of the rarest and often most aggressive forms of the disease. Her courageous journey, marked by rapid tumour growth, emergency surgery, and the unexpected trials of early menopause, now fuels her fervent advocacy for women to never dismiss their symptoms.
In August 2021, following a family holiday, Lisa experienced abdominal pain and discomfort that she attributed to irritable bowel syndrome (IBS) or a kidney infection. These common, benign conditions frequently mask the early signs of ovarian cancer, contributing to its late-stage diagnosis in many women. "I thought I had possibly a bit of IBS or a kidney problem or something like that. I was in quite a lot of pain," she recounted, highlighting the deceptive simplicity of her initial symptoms. The ease with which such critical indicators can be overlooked underscores the urgent need for greater awareness among both the public and healthcare professionals.
Recognising the persistent nature of her pain, Lisa made the crucial decision to call NHS 111, a non-emergency medical helpline. This call initiated a diagnostic pathway that would ultimately save her life. She was directed to a hospital in Coventry, where initial investigations revealed a 12cm cyst on her right ovary. Disturbingly, medical professionals initially deemed the cyst "not particularly sinister" and placed her on a waiting list for surgery. This initial assessment, while common for seemingly benign growths, proved to be a critical delay in Lisa’s case, showcasing the diagnostic challenges inherent in rare and rapidly progressing cancers.
The deceptive calm was short-lived. Within a mere month, Lisa witnessed an alarming transformation in her condition. The 12cm cyst, initially the size of a fist, had exploded in size, becoming palpable in her abdomen like a "football." The pain and discomfort intensified dramatically, alongside a profound emotional and physical exhaustion. This rapid progression is a hallmark of aggressive cancers and a stark warning sign that should prompt immediate re-evaluation. By December, follow-up scans confirmed the worst: the tumour had swelled to an astounding 20cm and was on the verge of rupturing. This critical development necessitated immediate intervention, transforming a scheduled procedure into an emergency.
Three days later, Lisa underwent an extensive emergency operation. The surgery involved the removal of the massive tumour, a fallopian tube, her appendix, and surrounding tissue. The removal of the appendix is often a protocol in mucinous ovarian cancer cases, as this specific subtype of ovarian cancer can sometimes originate from or spread to the appendix, or it can be a secondary site for mucinous tumours. Two weeks after this life-saving surgery, Lisa received the definitive diagnosis: mucinous ovarian cancer.
Mucinous ovarian cancer (MOC) represents a distinct and challenging subset of ovarian cancers. Unlike the more common serous subtype, MOC accounts for only about 2-3% of all ovarian cancer diagnoses in the UK, with Ovacome, a leading ovarian cancer charity, estimating around 200 new cases annually. Its rarity contributes to diagnostic difficulties, as healthcare providers may be less familiar with its presentation and progression. MOCs are characterised by their production of mucin, a jelly-like substance, and can grow to enormous sizes, often presenting as large, cystic masses. While sometimes associated with a better prognosis when caught early and confined to the ovary, advanced or ruptured MOC can be particularly aggressive and challenging to treat. Lisa’s experience underscores the rapid and potentially devastating growth pattern of this rare cancer, making early and accurate diagnosis paramount.
"Some ovarian cancers are really sneaky, hang around for years and you’ve got no sign of any symptoms at all," Lisa noted, reflecting on the varied nature of the disease. "The fact that mine grew so quickly was what alerted them as early as they did." This observation is crucial; while rapid growth might seem terrifying, in Lisa’s case, it inadvertently provided the urgency needed for medical professionals to act, ultimately leading to her diagnosis. Had the tumour grown more slowly, it might have remained undetected for longer, with potentially more dire consequences.
The subsequent months involved gruelling chemotherapy treatments, leading to hair loss and a profound physical toll. However, Lisa revealed that the most unexpected and challenging aspect of her recovery was not the visible side effects of chemotherapy, but an invisible, yet deeply impactful, consequence: early menopause. "I got chucked into early menopause and that was the bit I massively struggled with. I didn’t know what was depression and what was menopause," she candidly shared.
Chemotherapy and the surgical removal of ovaries, which produce essential hormones like oestrogen, frequently induce premature or early menopause in women undergoing ovarian cancer treatment. This abrupt hormonal shift can trigger a cascade of severe physical and psychological symptoms that can be profoundly debilitating. Lisa described a period of intense confusion and distress: "I didn’t know what was a cancer symptom and what was a menopause symptom. I couldn’t open the washing machine, the dishwasher or the oven. I couldn’t cook anything on the hob because I’d just have this awful hot flush. I was forgetting words. I was incredibly emotional." These symptoms – hot flashes, cognitive fog often referred to as "brain fog," mood swings, anxiety, and depression – are classic signs of menopause. When superimposed on the physical and emotional recovery from cancer treatment, they can create an overwhelming and isolating experience, often compounded by a lack of preparation or understanding from patients and sometimes even healthcare providers.
Today, Lisa Carroll stands as a testament to resilience. She is cancer-free and rapidly approaching the significant five-year milestone that will mark her formal discharge from oncology care. This five-year mark is often a critical benchmark in cancer survivorship, signifying a significantly reduced risk of recurrence. Despite her remarkable recovery, Lisa grapples with an emotion common among survivors: "I do not underestimate how fortunate I am that my long-term outlook is a lot brighter than for many," she said. "That brings with it a kind of survivor’s guilt." This complex psychological phenomenon highlights the enduring mental health challenges faced by those who have overcome life-threatening illnesses, often feeling guilt for their survival when others have not been as fortunate.
In her journey toward healing and acceptance, Lisa found an invaluable lifeline in Ovacome, the ovarian cancer charity. "They became my safe space," she reflected. "They helped me to connect with other people who understood what I was going through. They made an incredibly scary and isolating time feel far more manageable." The importance of patient support groups and charities like Ovacome cannot be overstated. They provide not only emotional solace and practical advice but also a community where individuals can share experiences, alleviate feelings of isolation, and find strength in collective understanding. These organisations play a crucial role in filling the gaps in formal medical care, addressing the holistic needs of patients and their families.
Now, Lisa is channeling her experience into advocacy, preparing to participate in Ovacome’s annual fundraising walk. The event, taking place at Cannon Hill Park in Birmingham on Saturday, serves as both a vital fundraiser for the charity’s support services and a powerful platform for raising public awareness. By sharing her story, Lisa hopes to empower other women to trust their instincts and seek medical help promptly when something feels amiss.
Her message is a potent reminder of the critical importance of symptom awareness for ovarian cancer. While there is no routine screening test for ovarian cancer for the general population, recognising persistent symptoms is the best defence. Key symptoms include persistent bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, and urinary symptoms such as needing to urinate more frequently or urgently. Any woman experiencing these symptoms for three weeks or more should consult her GP. Early diagnosis significantly improves treatment outcomes and survival rates. Lisa Carroll’s journey is a powerful call to action, urging every woman to be vigilant, to listen to her body, and to never underestimate the importance of advocating for her own health. In doing so, she hopes to transform her personal struggle into a beacon of hope and a catalyst for change for countless others.
